Търсене

HCP Privacy Notice

HCP Privacy Notice ОБЩО УВЕДОМЛЕНИЕ ЗА ЗАЩИТА НА ЛИЧНИТЕ ДАННИ НА МЕДИЦИНСКИТЕ СПЕЦИАЛИСТИ HCP Privacy Notice Learn more   Представителството на „Такеда“ ГмбХ (Takeda GmbH) в Република Българ...

www.takeda.com/bg-bg/hcp-privacy-notice/

Ако имате коментари или въпроси във връзка с обработката на Вашите данни от страна на Такеда, във връзка с настоящата методическа бележка, съдържанието на доклада за оповестяването на информация или с...

www.takeda.com/bg-bg/who-we-are/company-information/building-trust/transparency/2016/

1781-1944

Основаване-Модернизиране: 1781-1944 Learn more

www.takeda.com/bg-bg/who-we-are/company-information/history/1781-1944/

Nycomed’s novel anti-inflammatory therapy Daxas® (roflumilast) receives marketing authorisation in the European Union for patients with COPD

Nycomed’s novel anti-inflammatory therapy Daxas® (roflumilast) receives marketing authorisation in the European Union for patients with COPD Anti-inflammatory treatment aimed at patients with severe...

www.takeda.com/bg-bg/newsroom/news-releases/2010/nycomeds-novel-anti-inflammatory-therapy-daxas-roflumilast-receives-marketing-authorisation-in-the-european-union-for-patients-with-copd/

Nycomed and Forest Laboratories receive complete FDA response letter for Roflumilast – no additional patient trials were requested

Nycomed and Forest Laboratories receive complete FDA response letter for Roflumilast – no additional patient trials were requested For further information Media: General phone: +41 44 555 1...

www.takeda.com/bg-bg/newsroom/news-releases/2010/nycomed-and-forest-laboratories-receive-complete-fda-response-letter-for-roflumilast--no-additional-patient-trials-were-requested/

Nycomed’s novel anti-inflammatory therapy Daxas® (roflumilast) recommended for approval in the European Union for patients with COPD

Nycomed’s novel anti-inflammatory therapy Daxas® (roflumilast) recommended for approval in the European Union for patients with COPD For further information Media: General phone: +41 44 555...

www.takeda.com/bg-bg/newsroom/news-releases/2010/nycomeds-novel-anti-inflammatory-therapy-daxas-roflumilast-recommended-for-approval-in-the-european-union-for-patients-with-copd/

Резултати от търсенето

HCP Privacy Notice

2016_Archive

1781-1944

Nycomed’s novel anti-inflammatory therapy Daxas® (roflumilast) receives marketing authorisation in the European Union for patients with COPD

Nycomed and Forest Laboratories receive complete FDA response letter for Roflumilast – no additional patient trials were requested

Nycomed’s novel anti-inflammatory therapy Daxas® (roflumilast) recommended for approval in the European Union for patients with COPD

Nycomed on track in 2009

Нашите истории

Disclosure Report 2018.pdf

средства